

Donna A Wall

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5001540/publications.pdf>

Version: 2024-02-01

106
papers

6,968
citations

136740

32
h-index

60497

81
g-index

108
all docs

108
docs citations

108
times ranked

7769
citing authors

#	ARTICLE	IF	CITATIONS
1	Safety of allogeneic umbilical cord blood infusions for the treatment of neurological conditions: a systematic review of clinical studies. <i>Cytotherapy</i> , 2022, 24, 2-9.	0.3	14
2	Effect of Autograft CD34 + Dose on Outcome in Pediatric Patients Undergoing Autologous Hematopoietic Stem Cell Transplant for Central Nervous System Tumors. <i>Transplantation and Cellular Therapy</i> , 2022, 28, S252-S253.	0.6	1
3	Impact of CD34+ Cell Dose on Outcome Among Children Undergoing Autologous Hematopoietic Stem Cell Transplant for High-Risk Neuroblastomas. <i>Transplantation and Cellular Therapy</i> , 2022, 28, S251-S252.	0.6	1
4	CRISPR-Cas9 Gene Editing for Sickle Cell Disease and β^2 -Thalassemia. <i>New England Journal of Medicine</i> , 2021, 384, 252-260.	13.9	939
5	A Novel Secondary Neoplasm Following Allogeneic Hematopoietic Stem Cell Transplant: Mixed Donor-Recipient Primitive Mesenchymal Proliferation of the Liver. <i>Pediatric and Developmental Pathology</i> , 2021, 24, 366-370.	0.5	0
6	Delirium in Children Undergoing Hematopoietic Cell Transplantation: A Multi-Institutional Point Prevalence Study. <i>Frontiers in Oncology</i> , 2021, 11, 627726.	1.3	5
7	Allogeneic hematopoietic stem cell transplantation in an adolescent with Prader-Willi syndrome â€“ unique considerations. <i>Pediatric Hematology and Oncology</i> , 2021, , 1-7.	0.3	1
8	Sequential paternal haploidentical donor liver and HSCT in EPP allow discontinuation of immunosuppression postâ€“organ transplant. <i>Pediatric Transplantation</i> , 2021, 25, e14040.	0.5	4
9	Peripheral venous catheter collection of immune effector cells and hematopoietic stem cells is feasible and safe in older pediatric patients. <i>Transfusion</i> , 2021, 61, 3413-3419.	0.8	1
10	Effect of different conditioning regimens on survival and engraftment for children with hemophagocytic lymphohistiocytosis undergoing allogeneic hematopoietic stem cell transplantation: A single institution experience. <i>Pediatric Blood and Cancer</i> , 2020, 67, e28477.	0.8	5
11	Prevalence and Clinical Features of Inflammatory Bowel Diseases Associated With Monogenic Variants, Identified by Whole-Exome Sequencing in 1000 Children at a Single Center. <i>Gastroenterology</i> , 2020, 158, 2208-2220.	0.6	81
12	Safety and Efficacy of CTX001 in Patients with Transfusion-Dependent β^2 -Thalassemia and Sickle Cell Disease: Early Results from the Climb THAL-111 and Climb SCD-121 Studies of Autologous CRISPR-CAS9-Modified CD34+ Hematopoietic Stem and Progenitor Cells. <i>Blood</i> , 2020, 136, 3-4.	0.6	34
13	Expression and function of phosphoinositide 3â€“kinase delta in mesenchymal stromal cells from normal and leukaemic bone marrow. <i>British Journal of Haematology</i> , 2019, 185, 883-887.	1.2	5
14	Access to Hematopoietic Stem Cell Transplantation Among Pediatric Patients with Acute Leukemia: A Population-Based Analysis. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, S37-S38.	2.0	0
15	Access to Hematopoietic Stem Cell Transplantation among Pediatric Patients with Acute Lymphoblastic Leukemia: A Population-Based Analysis. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1172-1178.	2.0	7
16	Clinical presentation, immunologic features, and hematopoietic stem cell transplant outcomes for IKBKB immune deficiency. <i>Clinical Immunology</i> , 2019, 205, 138-147.	1.4	17
17	Aberrant splicing contributes to severe β^2 -spectrinâ€“linked congenital hemolytic anemia. <i>Journal of Clinical Investigation</i> , 2019, 129, 2878-2887.	3.9	24
18	Inducible indoleamine 2,3-dioxygenase 1 and programmed death ligand 1 expression as the potency marker for mesenchymal stromal cells. <i>Cytotherapy</i> , 2018, 20, 639-649.	0.3	49

#	ARTICLE	IF	CITATIONS
19	Disease burden and conditioning regimens in ASCT1221, a randomized phase II trial in children with juvenile myelomonocytic leukemia: A Children's Oncology Group study. <i>Pediatric Blood and Cancer</i> , 2018, 65, e27034.	0.8	26
20	A standardized immune phenotyping and automated data analysis platform for multicenter biomarker studies. <i>JCI Insight</i> , 2018, 3, .	2.3	29
21	Provincial Disparities in Access to Allogeneic Transplant in Canada. <i>Blood</i> , 2018, 132, 4742-4742.	0.6	0
22	Upper Versus Lower Endoscopy in the Diagnosis of Graft-Versus-Host Disease. <i>Journal of Clinical Gastroenterology</i> , 2017, 51, 701-706.	1.1	9
23	CD56 ^{bright} natural killer regulatory cells in filgrastim primed donor blood or marrow products regulate chronic graft- <i>versus</i> -host disease: the Canadian Blood and Marrow Transplant Group randomized 0601 study results. <i>Haematologica</i> , 2017, 102, 1936-1946.	1.7	20
24	Umbilical Cord Blood Transplantation in Children with Acute Leukemia: Impact of Conditioning on Transplantation Outcomes. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1714-1721.	2.0	24
25	Transplantation-associated thrombotic microangiopathy isolated to a congenital anomaly of the lung. <i>Pediatric Transplantation</i> , 2017, 21, e12824.	0.5	1
26	Enhanced human hematopoietic stem and progenitor cell engraftment by blocking donor T cell-mediated TNF signaling. <i>Science Translational Medicine</i> , 2017, 9, .	5.8	23
27	Interferon β induced compositional changes in human bone marrow derived mesenchymal stem/stromal cells. <i>Clinical Proteomics</i> , 2017, 14, 26.	1.1	30
28	Health-Related Quality of Life in Survivors of High-Risk Neuroblastoma After Stem Cell Transplant: A National Population-Based Perspective. <i>Pediatric Blood and Cancer</i> , 2016, 63, 1615-1621.	0.8	11
29	Long-Term Outcomes of Hematopoietic Stem Cell Transplantation for ZAP70 Deficiency. <i>Journal of Clinical Immunology</i> , 2016, 36, 713-724.	2.0	30
30	Carmustine-Free Conditioning Regimens Offer Comparable Efficacy to BEAM: The First Report of the Canadian Blood and Marrow Transplant Group Registry. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, S37-S38.	2.0	1
31	Umbilical Cord Blood (UCB) Transplantation in Children with Acute Leukemia: Impact of Conditioning Regimen on Transplant Outcomes. <i>Blood</i> , 2016, 128, 1231-1231.	0.6	1
32	Intergraft Variability in Nonhematopoietic Immunoregulatory Cell Number and Expression of Immune Checkpoint Inhibitor Receptors and Ligands in Both Allo- and Autografts: Potential Target for Intervention. <i>Blood</i> , 2016, 128, 3382-3382.	0.6	0
33	Routine filtration of hematopoietic stem cell products: the time has arrived. <i>Transfusion</i> , 2015, 55, 1980-1984.	0.8	2
34	IgH-V(D)J NGS-MRD measurement pre- and early post-allotransplant defines very low- and very high-risk ALL patients. <i>Blood</i> , 2015, 125, 3501-3508.	0.6	177
35	Functional Myeloid-Derived Suppressor Cell Subsets Recover Rapidly after Allogeneic Hematopoietic Stem/Progenitor Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1205-1214.	2.0	32
36	Long-Term Survival and Late Effects among One-Year Survivors of Second Allogeneic Hematopoietic Cell Transplantation for Relapsed Acute Leukemia and Myelodysplastic Syndromes. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 151-158.	2.0	49

#	ARTICLE	IF	CITATIONS
37	TNF-Receptor Inhibitor Therapy for the Treatment of Children with Idiopathic Pneumonia Syndrome. A Joint Pediatric Blood and Marrow Transplant Consortium and Children's Oncology Group Study (ASCT0521). <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 67-73.	2.0	62
38	Proteomic Analysis of Reprogramming of Mesenchymal Stem/Stromal Cells (MSC) Following Interferon Gamma Identifies Pathways That Are Upregulated in Suppression. <i>Blood</i> , 2015, 126, 384-384.	0.6	1
39	Randomized clinical trial of therapeutic music video intervention for resilience outcomes in adolescents/young adults undergoing hematopoietic stem cell transplant: A report from the Children's Oncology Group. <i>Cancer</i> , 2014, 120, 909-917.	2.0	127
40	One-Unit versus Two-Unit Cord-Blood Transplantation for Hematologic Cancers. <i>New England Journal of Medicine</i> , 2014, 371, 1685-1694.	13.9	246
41	Long-Term Survival and Late Effects Among 1-Year Survivors of Second Allogeneic Hematopoietic Cell Transplantation (2nd Allo HCT) for Relapsed Acute Leukemia and Myelodysplastic Syndrome: A Report from the CIBMTR. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, S64.	2.0	0
42	The addition of sirolimus to tacrolimus/methotrexate GVHD prophylaxis in children with ALL: a phase 3 Children's Oncology Group/Pediatric Blood and Marrow Transplant Consortium trial. <i>Blood</i> , 2014, 123, 2017-2025.	0.6	109
43	Plerixafor Successfully Rescues Poor Mobilizers Resulting in Adequate CD34 Cell Numbers However Stem Cell Products Yield Lower Numbers of CFU/CD34 and Delayed Neutrophil Engraftment. <i>Blood</i> , 2014, 124, 2450-2450.	0.6	16
44	A phase I study of histone deacetylase inhibitor, pracinostat (SB939), in pediatric patients with refractory solid tumors: IND203 a trial of the NCIC IND program/C17 pediatric phase I consortium. <i>Pediatric Blood and Cancer</i> , 2013, 60, 1868-1874.	0.8	42
45	Sirolimus Pharmacokinetics in Early Postmyeloablative Pediatric Blood and Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 569-575.	2.0	9
46	Children's Oncology Group's 2013 blueprint for research: Stem cell transplantation. <i>Pediatric Blood and Cancer</i> , 2013, 60, 1044-1047.	0.8	14
47	Clinical pharmacology of etoposide in children undergoing autologous stem cell transplantation for various solid tumours. <i>Xenobiotica</i> , 2013, 43, 276-282.	0.5	2
48	Striking Predictive Power For Relapse and Decreased Survival Associated With Detectable Minimal Residual Disease by IGH VDJ Deep Sequencing Of Bone Marrow Pre- and Post-Allogeneic Transplant In Children With B-Lineage ALL: A Subanalysis Of The COG ASCT0431/PBMTC ONC051 Study. <i>Blood</i> , 2013, 122, 919-919.	0.6	4
49	Recovery Of Myeloid Derived Suppressor Cell Subsets Following Allogeneic Hematopoietic Stem/Progenitor Cell Transplantation. <i>Blood</i> , 2013, 122, 4617-4617.	0.6	0
50	Late Effects in Hematopoietic Cell Transplant Recipients with Acquired Severe Aplastic Anemia: A Report from the Late Effects Working Committee of the Center for International Blood and Marrow Transplant Research. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 1776-1784.	2.0	30
51	Randomized Trial of Hydroxychloroquine for Newly Diagnosed Chronic Graft-versus-Host Disease in Children: A Children's Oncology Group Study. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 84-91.	2.0	56
52	Role of Cytotoxic Therapy with Hematopoietic Stem Cell Transplantation in the Treatment of Pediatric Acute Lymphoblastic Leukemia: Update of the 2005 Evidence-Based Review. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 505-522.	2.0	96
53	Transplantation in patients with SCID: mismatched related stem cells or unrelated cord blood?. <i>Blood</i> , 2012, 119, 2949-2955.	0.6	106
54	First- and Second-Line Systemic Treatment of Acute Graft-versus-Host Disease: Recommendations of the American Society of Blood and Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 1150-1163.	2.0	506

#	ARTICLE	IF	CITATIONS
55	Expanding Spectrum of Malignancies in ALPS: A Cancer Predisposing Syndrome?.. Blood, 2012, 120, 2149-2149.	0.6	3
56	No Survival Advantage After Double Umbilical Cord Blood (UCB) Compared to Single UCB Transplant in Children with Hematological Malignancy: Results of the Blood and Marrow Transplant Clinical Trials Network (BMT CTN 0501) Randomized Trial. Blood, 2012, 120, 359-359.	0.6	11
57	The Relationship of Acute Gvhd and Pre- and Post-Transplant Flow-MRD to the Incidence and Timing of Relapse in Children Undergoing Allogeneic Transplantation for High Risk ALL: Defining a Target Population and Window for Immunological Intervention to Prevent Relapse. Blood, 2012, 120, 470-470.	0.6	4
58	Publication bias is present in blood and marrow transplantation: an analysis of abstracts at an international meeting. Blood, 2011, 118, 6698-6701.	0.6	20
59	Phase I study of tandem high-dose chemotherapy with autologous peripheral blood stem cell rescue for children with recurrent brain tumors: A pediatric blood and marrow transplant consortium study. Pediatric Blood and Cancer, 2011, 57, 506-513.	0.8	25
60	A Randomized Trial of Sirolimus-Based Graft Versus Host Disease (GVHD) Prophylaxis After Hematopoietic Stem Cell Transplantation (HSCT) in Selected Patients with CR1 and CR2 ALL: Results From Children's Oncology Group Study ASCT0431. Blood, 2011, 118, 837-837.	0.6	1
61	Allogeneic Hematopoietic Cell Transplantation (HCT) for Neuroblastoma (NB): The CIBMTR Experience. Blood, 2011, 118, 3074-3074.	0.6	0
62	Umbilical cord blood: importance of supporting public banks. American Family Physician, 2011, 84, 638.	0.1	2
63	Safety, efficacy, and pharmacokinetics of intravenous busulfan in children undergoing allogeneic hematopoietic stem cell transplantation. Pediatric Blood and Cancer, 2010, 54, 291-298.	0.8	33
64	Regulatory issues in cord blood banking and transplantation. Best Practice and Research in Clinical Haematology, 2010, 23, 171-177.	0.7	17
65	Phase I study of paclitaxel with standard dose ifosfamide in children with refractory solid tumors: A Pediatric Oncology Group study (POG 9376). Pediatric Blood and Cancer, 2009, 52, 346-350.	0.8	16
66	A Phase I/II study of the safety and efficacy of the addition of sirolimus to tacrolimus/methotrexate graft-versus-host disease prophylaxis after allogeneic haematopoietic cell transplantation in paediatric acute lymphoblastic leukaemia (ALL). British Journal of Haematology, 2009, 147, 691-699.	1.2	27
67	Recent Decrease in Acute Graft-versus-Host Disease in Children with Leukemia Receiving Unrelated Donor Bone Marrow Transplants. Biology of Blood and Marrow Transplantation, 2009, 15, 360-366.	2.0	43
68	Methodology for Updating Published Evidence-Based Reviews Evaluating the Role of Blood and Marrow Transplantation in the Treatment of Selected Diseases: A Policy Statement by the American Society for Blood and Marrow Transplantation. Biology of Blood and Marrow Transplantation, 2009, 15, 761-762.	2.0	9
69	Modest Prolongation of Survival for Patients 60-80 Year at Time of Acute Myelogenous Leukemia (AML) Diagnosis Who Are Treated with Conventional AML Therapy: A Provincial Cohort Analysis.. Blood, 2009, 114, 4125-4125.	0.6	0
70	Comparison of Outcomes of Mismatched Related Stem Cell and Unrelated Cord Blood Transplants in Children with Severe T-Cell Deficiencies.. Blood, 2009, 114, 664-664.	0.6	1
71	Biomarkers in newly diagnosed pediatric-extensive chronic graft-versus-host disease: a report from the Children's Oncology Group. Blood, 2008, 111, 3276-3285.	0.6	143
72	Altered Toll-Like Receptor 9 Responses in Circulating B Cells at the Onset of Extensive Chronic Graft-versus-Host Disease. Biology of Blood and Marrow Transplantation, 2007, 13, 386-397.	2.0	81

#	ARTICLE	IF	CITATIONS
73	Results of the Cord Blood Transplantation Study (COBLT): Outcomes of Unrelated Donor Umbilical Cord Blood Transplantation in Pediatric Patients with Lysosomal and Peroxisomal Storage Diseases. <i>Biology of Blood and Marrow Transplantation</i> , 2006, 12, 184-194.	2.0	178
74	Hematopoietic Stem Cell Transplantation After First Marrow Relapse of Non-T, Non-B Acute Lymphoblastic Leukemia. <i>Journal of Pediatric Hematology/Oncology</i> , 2006, 28, 210-215.	0.3	10
75	Collection, storage, and infusion of stem cells in children with high-risk neuroblastoma: Saving for a rainy day. <i>Pediatric Blood and Cancer</i> , 2006, 46, 719-722.	0.8	19
76	Use of G-CSF in Matched Sibling Donor Pediatric Allogeneic Transplantation: A Consensus Statement from the Children's Oncology Group (COG) Transplant Discipline Committee and Pediatric Blood and Marrow Transplant Consortium (PBMT) Executive Committee. <i>Pediatric Blood and Cancer</i> , 2006, 46, 414-421.	0.8	46
77	Inflammatory Markers and Autoantibodies That Correlate with Early and Late Onset of New Onset Pediatric Chronic Graft-Versus-Host Disease (GVHD).. <i>Blood</i> , 2006, 108, 3232-3232.	0.6	1
78	Primary Graft Failure (GF) after Unrelated Donor Cord Blood Transplants (UCBT): Risk Factors and Management.. <i>Blood</i> , 2006, 108, 44-44.	0.6	3
79	Fewer Relapses Following Unrelated Donor Cord Blood (UDCB) Compared to Related or Unrelated Bone Marrow (BM) or Peripheral Blood Cell (PBSC) Transplant in the Treatment of Childhood Relapsed and Very High Risk Acute Lymphoblastic Leukemia (ALL).. <i>Blood</i> , 2006, 108, 3153-3153.	0.6	0
80	Low Rates of Toxicity, GVHD, and Relapse Using Sirolimus (SRL)-Based GVHD Prophylaxis in Pediatric Related and Unrelated Transplant Recipients with High-Risk ALL.. <i>Blood</i> , 2006, 108, 2876-2876.	0.6	0
81	Transplantation of Umbilical-Cord Blood in Babies with Infantile Krabbe's Disease. <i>New England Journal of Medicine</i> , 2005, 352, 2069-2081.	13.9	642
82	Umbilical cord blood transplantation in adults: Results of the prospective cord blood transplantation (COBLT). <i>Biology of Blood and Marrow Transplantation</i> , 2005, 11, 149-160.	2.0	137
83	Busulfan/Melphalan/Antithymocyte Globulin Followed by Unrelated Donor Cord Blood Transplantation for Treatment of Infant Leukemia and Leukemia in Young Children: The Cord Blood Transplantation Study (COBLT) Experience. <i>Biology of Blood and Marrow Transplantation</i> , 2005, 11, 637-646.	2.0	76
84	The Evolution of the Evidence-Based Review: Evaluating the Science Enhances the Art of Medicine—Statement of the Steering Committee for Evidence-Based Reviews of the American Society for Blood and Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2005, 11, 819-822.	2.0	19
85	The Role of Cytotoxic Therapy with Hematopoietic Stem Cell Transplantation in the Therapy of Acute Lymphoblastic Leukemia in Children: An Evidence-Based Review. <i>Biology of Blood and Marrow Transplantation</i> , 2005, 11, 823-861.	2.0	67
86	Umbilical Cord Blood Stem Cell Transplantation in Severe T-Cell Immunodeficiency Disorders. <i>Pediatric Asthma, Allergy and Immunology</i> , 2005, 18, 189-200.	0.2	0
87	Post-Thaw Colony Forming Unit (CFU) Counts and Yield Are the Most Important Predictors of Engraftment and Survival Following Unrelated Donor Cord Blood Transplantation (CBT): A COBLT Study Report.. <i>Blood</i> , 2005, 106, 2046-2046.	0.6	1
88	Eosinophilia, Positive ANA, and Hypergammaglobulinemia at Presentation of Extensive Chronic GVHD in Children: A Children's Oncology Group Study.. <i>Blood</i> , 2005, 106, 5375-5375.	0.6	0
89	Micafungin versus Fluconazole for Prophylaxis against Invasive Fungal Infections during Neutropenia in Patients Undergoing Hematopoietic Stem Cell Transplantation. <i>Clinical Infectious Diseases</i> , 2004, 39, 1407-1416.	2.9	1,248
90	Higher Cell Dose and CD34+ Content Improves Engraftment Following Unrelated Donor Cord Blood Transplantation (CBT): A Report of the National Marrow Donor Program (NMDP) Cord Blood (CB) Experience.. <i>Blood</i> , 2004, 104, 975-975.	0.6	1

#	ARTICLE	IF	CITATIONS
91	Valganciclovir for the Early Prophylaxis of Cytomegalovirus (CMV) Infection after Allogeneic Stem Cell Transplantation.. Blood, 2004, 104, 5074-5074.	0.6	0
92	Umbilical cord blood transplantation in Wiskott Aldrich syndrome. Journal of Pediatrics, 2003, 142, 519-523.	0.9	49
93	Unrelated marrow transplantation for children with acute lymphoblastic leukemia in second remission. Blood, 2002, 99, 3151-3157.	0.6	77
94	Human umbilical cord blood cells can be induced to express markers for neurons and glia. Cell Transplantation, 2002, 11, 261-4.	1.2	24
95	Cyclophosphamide Plus Topotecan in Children With Recurrent or Refractory Solid Tumors: A Pediatric Oncology Group Phase II Study. Journal of Clinical Oncology, 2001, 19, 3463-3469.	0.8	293
96	Umbilical cord blood transplantation in severe T-cell immunodeficiency disorders: two-year experience. Journal of Clinical Immunology, 2000, 20, 466-476.	2.0	82
97	The contribution of nonmalignant tumors to CNS tumor incidence rates among children in the United States. Cancer Causes and Control, 1999, 10, 101-105.	0.8	50
98	Jumping Translocations of 3q in Acute Promyelocytic Leukemia. Cancer Genetics and Cytogenetics, 1999, 108, 149-153.	1.0	10
99	A child with reading impairment and a family history of adrenoleukodystrophy. Seminars in Pediatric Neurology, 1999, 6, 233-237.	1.0	3
100	Association of reticular dysgenesis (thymic aplasia and congenital aleukocytosis) with bilateral sensorineural deafness. Journal of Pediatrics, 1999, 135, 387-389.	0.9	29
101	Kinetics of T-cell development of umbilical cord blood transplantation in severe T-cell immunodeficiency disorders. Journal of Allergy and Clinical Immunology, 1999, 103, 823-832.	1.5	46
102	Bone marrow transplantation for the treatment of β -mannosidosis. Journal of Pediatrics, 1998, 133, 282-285.	0.9	50
103	Expression of Human Alpha1Antitrypsin in Murine Hematopoietic Cells in Vivo after Retrovirus-Mediated Gene Transfer. Molecular Genetics and Metabolism, 1998, 63, 198-204.	0.5	10
104	Thiotepa and Cyclophosphamide with Stem Cell Rescue for Consolidation Therapy for Children with High-Risk Neuroblastoma. Journal of Pediatric Hematology/Oncology, 1998, 20, 49-54.	0.3	28
105	Infant Cancer in the U.S.. Journal of Pediatric Hematology/Oncology, 1997, 19, 428-432.	0.3	235
106	Abnormal in vitro thymocyte differentiation in a patient with severe combined immunodeficiency-Nezelof's syndrome. Journal of Clinical Immunology, 1996, 16, 151-158.	2.0	10